Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of$ 1.03. This compares to a loss of $1.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +3.88%. A quarter ago, it was expected that this company would post a loss of$ 1.26 per share when it actually produced a loss of $1.1, delivering a surprise of +12.7%. Over the last four quarters, the compa ...